Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
ipo
27
×
national blog main
life sciences
biotech
national top stories
boston blog main
texas blog main
texas top stories
boston top stories
san francisco blog main
new york blog main
san francisco top stories
new york top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
fda
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
startups
venture capital
clinical trials
deals
medical devices
eli lilly
funding
novartis
texas
vc
What
bio
ipo
roundup
company
medicines
new
public
latest
life
million
science
cancer
drugs
medicine
news
pharmaceutical
research
tech
therapeutics
week
based
biotech
companies
developing
firms
innovation
let’s
moves
raised
san
software
texas
today
tx
way
years
antonio
big
biotechs
black
Language
unset
Current search:
ipo
×
@engadget.com
3 years ago
23andMe is going public as it pushes further into healthcare
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
San Antonio to Honor Regenerative Medicine Pioneer Stephen Badylak
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
San Antonio Wound-Care Company Eyes (Another) Initial Public Offering
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
GrainChain, Chargify, Q2, Hypergiant, NASA Tech & More TX Tech
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Upland Software, Bumble in India, Cratejoy Layoffs, & More TX Tech
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
6 years ago
Exits in Austin, Pitch NASA, Diversity in Energy, & More TX Tech
@xconomy.com
6 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@techcrunch.com
6 years ago
Public shareholders got high today on Tilray, the first marijuana company to IPO on Nasdaq
@xconomy.com
6 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
6 years ago
OncoNano, Maker of Tumor Imaging Technology, Raises $11.7 Million